Skip to Content
  • Perspective
  • Open Access

16 September 2024

13 Pages

Polypills in the Management of Cardiovascular Risk—A Perspective

,
and
1
Hcor Research Institute, Hcor (IP-Hcor), Abílio Soares Street 250, São Paulo 04004-050, Brazil
2
Division of Health Care Sciences, Dresden International University, Freiberger Str. 37, 01067 Dresden, Germany
3
Department of Psychotherapy and Psychosomatic Medicine, Faculty of Medicine, TUD Dresden University of Technology, Fetscherstrasse 74, 01307 Dresden, Germany
4
Department of Neurology, Medical Faculty and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Fetscherstrasse 74, 01307 Dresden, Germany
This article belongs to the Section Pharmacology

Abstract

Cardiovascular disease and cardiovascular risk factors are global healthcare problems, given their high prevalence and the recognized low rates of adequate control despite the abundant body of evidence on different therapeutic options. The World Heart Federation has scrutinized the reasons for poor control of cardiovascular risk factors. Among these reasons, patients’ poor adherence to treatment regimens as well as limited rates of evidence-based therapy prescription from healthcare providers play a substantial role in the challenge of cardiovascular risk management. Polypills are fixed-dose combinations including two or more active drugs, from different pharmacological classes, combined in a single dosage form. Polypills were designed to simplify the clinical management of pharmacotherapy and increase adherence to treatment. From this perspective, we discuss the current literature on the use of polypills in the primary and secondary prevention of cardiovascular disease as well as future challenges and the potentials of this treatment strategy.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.